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Abstract
Introduction Relative oxidation of different metabolic substrates in the heart varies both physiologically and pathologi-
cally, in order to meet metabolic demands under different circumstances. 13C labelled substrates have become a key tool for 
studying substrate use—yet an accurate model is required to analyse the complex data produced as these substrates become 
incorporated into the Krebs cycle.
Objectives We aimed to generate a network model for the quantitative analysis of Krebs cycle intermediate isotopologue dis-
tributions measured by mass spectrometry, to determine the 13C labelled proportion of acetyl-CoA entering the Krebs cycle.
Methods A model was generated, and validated ex vivo using isotopic distributions measured from isolated hearts perfused 
with buffer containing 11 mM glucose in total, with varying fractions of universally labelled with 13C. The model was then 
employed to determine the relative oxidation of glucose and triacylglycerol by hearts perfused with 11 mM glucose and 
0.4 mM equivalent Intralipid (a triacylglycerol mixture).
Results The contribution of glucose to Krebs cycle oxidation was measured to be 79.1 ± 0.9%, independent of the fraction of 
buffer glucose which was U-13C labelled, or of which Krebs cycle intermediate was assessed. In the presence of Intralipid, 
glucose and triglyceride were determined to contribute 58 ± 3.6% and 35.6 ± 0.8% of acetyl-CoA entering the Krebs cycle, 
respectively.
Conclusion These results demonstrate the accuracy of a functional model of Krebs cycle metabolism, which can allow 
quantitative determination of the effects of therapeutics and pathology on cardiac substrate metabolism.
Keywords Krebs cycle · TCA cycle · Isotopomer analysis · Fluxomics · Metabolic substrate switching · LC–MS/MS · Heart
1 Introduction
Stable isotope labelling has been an invaluable tool for the 
study of metabolic fluxes. An important use of 13C labelled 
metabolites has been to investigate the proportional con-
tribution of different substrates to the Krebs cycle under 
varying conditions and across different tissues. This has 
generated many insights, particularly when used in studies 
of the isolated perfused heart where there can be significant 
changes in substrate selection under different pathological 
and physiological conditions (Aubert et al. 2016; Crown 
et al. 2016; Liu et al. 2016; Lloyd et al. 2003, 2004). Inter-
pretation of the isotopic distribution of Krebs cycle inter-
mediates arising in such studies is far from trivial, however, 
and a reliable model is therefore required.
Mass spectrometry is a very sensitive approach for meas-
uring the concentrations of Krebs cycle intermediates (Katzs 
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et al. 1993; Taegtmeyer et al. 2016; Yang et al. 2008). The 
proportion of each intermediate which is 1–6 units heavier 
as a result of 13C labelling is also directly detectable, and 
thus, differences in the proportion of 13C labelled metabolic 
substrate oxidation are detected in the labelling patterns. 
The complexity of carbon flux in the Krebs cycle means a 
model is required to accurately assign a given labelling pat-
tern to a proportion of labelled substrate oxidation, particu-
larly in situations where multiple substrates may be present. 
There have been multiple offerings for large scale models of 
cardiac metabolism, as reviewed in Taegtmeyer et al. (2016). 
Briefly, whilst large scale stoichiometric models consider the 
proportional metabolism of compounds into their products, 
kinetic models employ information about the rate constants 
of the enzymes involved to determine flux. However, for a 
simple and easily applicable analysis of isotopologue distri-
bution data, it is important to consider not only the flux of 
molecules through enzymes, but also migration of labelled 
carbons within the molecules themselves. Therefore, we 
propose an easy to apply network model which accounts for 
both the stoichiometry between molecules in the network, 
and also that between isotopomers.
To generate such a model, there are several considera-
tions which must be taken into account. 13C originating from 
metabolism of  U13C labelled fatty acids and carbohydrates 
primarily enters the Krebs cycle as [1,2-13C2]acetyl-CoA. 
However, stereochemistry and the cyclic nature of the path-
way leads to a complex distribution of isotopomers (mol-
ecules with equivalent numbers of labelled and unlabelled 
carbon atoms, but differing in their positions) and isotopo-
logues (molecules with different numbers of labelled and 
unlabelled carbons) at steady state. Incorporation of 2 + amu 
acetyl-CoA (labelled with two 13C atoms) into the Krebs 
cycle to initially form a 2 + amu citrate isotopologue results 
in the generation of a greater number of isotopologues of 
succinate, malate and other intermediates through subse-
quent cycles than can be accounted for by considering 2 + 
amu intermediates alone. Indeed, the full range of citrate 
isotopologues with 1–6 + amu can all result from an input 
of [1,2-13C] acetyl-CoA.
The cyclic nature of the Krebs cycle (Krebs et al. 1938) 
thus leads to amplification of labelling at equilibrium. Whilst 
the greatest mass increase an intermediate could gain from 
a single turn of the cycle with the input of [1,2-13C2] acetyl-
CoA would be 2 + amu, the resulting 2 + amu oxaloacetate 
can yield 2 + and 4 + labelled citrate when combined with 
unlabelled and [1,2-13C2]acetyl-CoA, respectively. Over a 
number of cycles towards steady state, this results in an array 
of isotopologues.
Furthermore, two carbons are removed as  CO2 during 
each turn of the cycle based upon their position in isocitrate 
and α-ketoglutarate, and indiscriminately of atomic mass 
(Krebs et al. 1938). Since fumarate is non-enantiomeric, 
[1,2-13C]fumarate is equally likely to become 1,2 or 3,4 
13C labelled malate when hydrated across its double bond 
(Fig. 1). When acetyl-CoA reacts with the resulting oxaloac-
etate, one 13C carbon from [1,2-13C]oxaloacetate will arrive 
in a position on isocitrate where it is to be lost as 13CO2, 
whilst one 13C from [3,4-13C]oxaloacetate will be removed 
by α-ketoglutarate dehydrogenase. The outcome of this is 
that a single 13C is lost from some labelled intermediates, 
and the position of the remaining 13C varies, thereby affect-
ing its future fate. This further complicates the distribution 
of isotopologues produced at steady state.
Here we present a mathematical model which takes the 
full complexity of the Krebs cycle into account. The model 
can map 13C accumulation within the cycle to steady state 
and has been used to calculate the relative oxidation of dif-
ferent metabolites in a perfused heart system.
2  Methods
2.1  Animal work
Rats used in this study were euthanised using an approved 
Schedule 1 method by a competent, personal licence holder 
in accordance with the Animals in Scientific Procedures 
Act 1986 and UK Home Office guidance. Animals were 
given standard chow and water ad libitum and housed in a 
12 h/12 h light/dark cycle.
2.2  Materials
All reagents and chemicals were obtained from Sigma-
Aldrich Ltd (UK) unless otherwise stated.
2.3  Generation of the model
2.3.1  Initial conditions
The initial proportion of 13C labelled Krebs cycle intermedi-
ates before the administration of any label was taken to be 
0, and the proportion of entirely unlabelled intermediates 1. 
The proportion of the acetyl-CoA input which was [1,2-13C2] 
acetyl-CoA was designated α.
2.3.1.1 Mapping the relationships of Krebs cycle isotopom‑
ers The initial iterations of the Krebs cycle were worked 
through until every isotopomer possible for each intermedi-
ate had been introduced, and all were assigned a tag (C1, 
C2,… for citrate; A1, A2,… for α-ketoglutarate etc.). Four 
metabolites were crucial to the model—the 6-carbon inter-
mediate citrate; the 5-carbon intermediate α-ketoglutarate; 
the non-stereochemical 4-carbon intermediate succinate, 
and the stereochemical 4-carbon intermediate malate. The 
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isotopologue or isotopomer distributions of each of the 
other intermediates would be identical to one of these other 
metabolites, and therefore were not incorporated into the 
model for the purpose of calculating enrichment.
The relationship between each isotopomer at time T to 
the isotopomers of the preceding ‘crucial’ metabolite in the 
cycle at time T − 1 were drawn up as a set of differential 
equations. For example, if 1 + malate labelled on the alpha-
carbon is designated M1, M1(T) = 0.5 S6 (T − 1), where S6 
corresponds to the 1  + succinate isotopomer labelled on 
the carbon at the end of the chain. The fate of the 50% of 
S6 not converted to M1 is to become 1 + malate labelled at 
the carbon on the opposite end of the chain to the α-carbon, 
which we can designate M2 to get the equation M2(T) = 0.5 
S6 (T − 1) and so on. Atom transitions for the metabolic net-
work adhering to the guidelines of Crown and Antoniewicz 
(2013) can be found in Supplementary Tables 1–3.
Next, a network model was generated. This was achieved 
by multiplying a 1 by 78 vector comprising the 78 isotopom-
ers of citrate, α-ketoglutarate, succinate and malate at time T 
Fig. 1  Movement of labelled 
carbons during one turn of the 
Krebs cycle. Black represents 
a 13C labelled carbon, and red 
represents an unlabelled one. 
Labelled citrate with + 2 amu, 
formed from oxaloacetate and 
[1,2-13C]acetyl-CoA, is equally 
likely to produce one of two 
different isotopologues of 
oxaloacetate with + 2 amu
 R. T. Lindsay et al.
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with a 78 by 78 network matrix comprising the relationships 
of those isotopomers to each other.
The model then assigned values for α to experimentally-
obtained data by running iterations to determine which value 
of α corresponded to the smallest discrepancy between pre-
dicted and experimentally-measured isotopic distributions. 
This discrepancy score has been detailed for each α value 
presented in this paper, where a discrepancy score of 0 rep-
resents the perfect fit, and 1 the worst possible fit.
2.4  Validation of the model in the isolated rat heart
2.4.1  Perfusion protocols
Male Wistar rats (300–350 g, ~ 9 weeks old) were obtained 
from a commercial breeder (Charles River, UK). Rats were 
euthanised by rising  CO2 concentrations, followed by cervi-
cal dislocation.
Hearts were excised and perfused in the Langendorff 
mode at 38 °C and a constant pressure of 100 mmHg for 
32 min, following an initial acclimatisation period. This 
time period is sufficient for carbon labelling in the perfused 
heart to reach steady state as shown by others previously 
(Chatham et al. 1995; Khairallah et al. 2004; Lewandowski 
and Hulbert 1991). We recognise that all isolated heart prep-
arations are subtly different, and the possibility exists that 
ours may require more time to reach steady state compared 
to those in the aforementioned studies. However, given the 
similarity of our preparation to those mentioned, we have 
made the assumption that our preparation reached metabolic 
steady state in a similar time period. The perfusion medium 
was 250 mL of recirculating Krebs–Henseleit (KH) buffer 
with the basic composition 118 mM NaCl, 4.7 mM KCl, 
1.2 mM  MgSO4, 1.3 mM  CaCl2, 0.5 mM EDTA, 25 mM 
 NaHCO3 and 1.2 mM  KH2PO4. The KH buffer was pH 7.4, 
and gassed with 95%  O2, 5%  CO2.
To validate that α determination was consistent when 
input percentages of  U13C labelled glucose differed, the 
buffer was supplemented with 11 mM glucose. In separate 
experiments, 0%, 25%, 50%, 75% or 100% of this glucose 
was  U13C labelled, while the remaining percentage remained 
unlabelled (n = 3 per condition).
Relative input of triacylglycerol and glucose from the 
perfusion buffer to the Krebs cycle was then determined 
in hearts perfused with both 11 mM glucose and 0.4 mM 
equivalent triacylglycerol mixture in the form of Intralipid, 
which would yield 1.2 mM fatty acid and 0.4 mM glyc-
erol upon hydrolysis (composition of Intralipid detailed in 
Supplementary Table 4). The KH buffer contained either 
8.25 mM unlabelled glucose, 2.75 mM U-13C labelled glu-
cose (99% enrichment, Cambridge Isotopes Laboratories) 
and 0.4 mM Intralipid (n = 6); or 11 mM unlabelled glucose, 
0.1 mM U-13C mixed triglycerides (99.6% enrichment Cam-
bridge Isotopes Laboratories) and 0.3 mM unlabelled tria-
cylglycerol in the form of Intralipid (n = 6).
At the end of the perfusion protocol, the left ventricle was 
rapidly sectioned in transverse and snap frozen for analysis 
by LC–MS/MS.
2.5  Liquid chromatography‑coupled mass 
spectrometry (LC–MS)
Isotopologue distributions of malate, citrate, glutamate 
(the cellular pool of which rapidly interconverts with 
α-ketoglutarate) and succinate were determined using 
LC–MS according to the MSI standards detailed in Sup-
plementary Table 5.
Metabolites were extracted from heart samples using a 
methanol/chloroform/water extraction method as described 
previously (Le Belle et al. 2002). The resulting aqueous and 
organic phases were collected and dried by evacuated cen-
trifuge before reconstitution in 10 mM ammonium acetate/
internal standard mixture (200 µL; phenylalanine d5, Valine 
d8, leucine d10). Samples were run for 6 min on a Thermo 
Dionex Ultimate 3000 LC system using an ACE Excel-2 
C18-PFP 5  μm column (100 A, 150 × 2.1  mm, 30  °C). 
Mobile phase A was 0.1% formic acid, while mobile phase B 
was acetonitrile plus 0.1% formic acid. The LC gradient was 
as follows: 0% B for 1.6 min followed by a linear gradient up 
to 30% B for 2.4 min. Following a further linear increase to 
90% B over 30 s, B was held at 90% for 30 s before 1.5 min 
re-equilibration.
The LC system was coupled to a Thermo Elite orbitrap 
mass spectrometer, on which run parameters were as fol-
lows: Heater temp 420 °C, sheath gas flow rate 60 units, 
Aux gas flow rate 20 units, Sweep gas flow rate 5 units. The 
spray voltage was − 2.5, capillary temp 380 °C and S-lens 
RF level 60%. The raw peak areas obtained from mass spec-
tra were inputted to the model without correcting for natural 
isotopologue abundance, as this natural abundance varies 
by an unknown factor which is in inverse proportion to the 
unknown value α.
Glutamate was measured as a proxy for α-ketoglutarate. 
Glutamate is interconverted rapidly with α-ketoglutarate and 
therefore their labelling distributions are identical (Chatham 
et al. 1995; Lewandowski et al. 1996; Melo et al. 2011; Yu 
et al. 1995).
The 6 + amu isotopologue of citrate also had a high limit 
of detection, and therefore in conditions where the 6 + amu 
isotopologue of citrate was expected citrate has not been 
considered in the fitting of the model.
A model for determining cardiac mitochondrial substrate utilisation using stable 13C-labelled…
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2.6  Statistical analysis
All results are displayed as mean ± SEM. 2-way ANOVA 
was employed with the percentage of buffer glucose which 
was U-13C labelled as one factor and the metabolite assessed 
as the other, to determine whether either factor affected the 
proportion of total oxidation which the model calculated to 
be accounted for by glucose oxidation.
3  Results and discussion
3.1  Prediction of isotopologue distribution in Krebs 
cycle metabolites
The model was used to predict isotopologue distributions of 
malate, citrate, α-ketoglutarate and succinate at every value 
of α between 0 and 1. The predicted proportion of each inter-
mediate’s total cellular pool accounted for by each isotopo-
logue at each value of α was visualised by plotting α against 
the predicted steady state distribution of isotopologues, giv-
ing the bifurcation plots shown in Fig. 2. The model predicts 
the unlabelled isotopologue of each intermediate to decrease 
as the proportion of 2 + amu acetyl-CoA entering the cycle 
increases. Meanwhile, the fully labelled isotopologue 
increases with rising α. Each of the other isotopologues are 
predicted to reach their own peak as α increases, decreasing 
again to 0 as the proportion of [1,2-13C2]acetyl-CoA entering 
the Krebs cycle continues to rise.
3.2  Validation of the model
When the proportion of labelled glucose provided in the 
perfusion buffer was varied, and the resulting steady-state 
Fig. 2  Bifurcation plots showing how the relative proportions of key Krebs cycle intermediate isotopologues vary at equilibrium as the propor-
tion of [1,2-13C2]acetyl-CoA entering the Krebs cycle (α) increases, as predicted by the model
 R. T. Lindsay et al.
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isotopologue distributions determined by LC–MS, α was fit-
ted separately for each experimental replicate, using each of 
malate, glutamate and succinate independently. Citrate was 
not considered here because of the higher labelling concen-
trations used, and the higher concentration of 6 + amu citrate 
which would result. The value of α assigned to these by the 
model was largely consistent (Fig. 3), and the discrepancy 
of fit values all lower than 0.065 (Supplementary Materials). 
Across three different intermediates, and hearts supplied 
with four different proportions of U-13C glucose, the average 
calculated contribution of glucose was 79.1% ± 0.9% SEM. 2 
way ANOVA indicated the percentage of Krebs cycle oxida-
tion accounted for by glucose oxidation was not affected by 
the percentage of buffer glucose which was  U13C labelled, 
by which intermediate was assessed, or by any interaction 
between factors (all p > 0.05). Thus, it seems the model is 
an accurate tool for analysing how [1,2-13C2]acetyl-CoA is 
incorporated into the Krebs cycle and is effective across the 
whole range of labelling inputs irrespective of intermediate 
measured. The remaining ~ 20% of acetyl-CoA entering the 
TCA cycle which cannot be accounted for by buffer glucose 
oxidation most likely stems from catabolism of endogenous 
unlabelled triacylglycerol and glycogen stores.
3.3  Determination of the relative oxidation 
of substrates in an isolated heart preparation
When 0.4 mM equivalent Intralipid was added to the per-
fusion buffer and 25% of the glucose was U-13C labelled, 
the isotopologue distributions shown in Fig. 4b were pro-
duced, as measured by LC–MS. Given the agreement of 
α values fitted from each individual metabolite in Fig. 3, 
citrate, glutamate, succinate and malate were used simulta-
neously to fit α. It was appropriate to use citrate because of 
the low levels of labelling used, and therefore the low level 
of 6 + amu citrate expected. The observed isotopologue 
distributions were calculated by the model to most closely 
fit those predicted when α = 0.145 (± 0.009) (Fig. 4a), a 
fit which gave the discrepancy score of 0.0139 (± 0.0005). 
Since only ¼ of the buffer glucose was labelled, relative 
contribution of glucose to Krebs cycle oxidation is four 
times 14.5%, at 58.0 ± 3.6%.
The accuracy of the model was then corroborated by 
determining α when the labelled acetyl-CoA originated 
from the triacylglycerol in the perfusion buffer. Label-
ling 25% of the perfusion buffer triacylglycerol resulted 
in smaller proportions of labelled isotopologues than 
with the labelled glucose when measured by LC–MS 
(Fig. 4d). The model determined α to be 0.089 ± 0.002, 
a 35.6 ± 0.8% contribution of perfusion buffer Intralipid 
oxidation to total Krebs cycle oxidation. The predicted iso-
topologue distribution for α = 0.089 again closely matched 
the observed experimental data, with a discrepancy score 
of 0.0105 (± 0.0002).
This helps to confirm the validity of the model, as 
together triacylglycerol oxidation (35.6%) and glucose oxi-
dation (58.0%) account for almost 100% of the acetyl-CoA 
entering the Krebs cycle in this preparation. The remain-
ing 6–7% of oxidised acetyl-CoA likely corresponds to 
oxidation of endogenous lipid and glycogen stores. This 
is a lower figure than the 20% endogenous substrate oxi-
dation observed when no Intralipid was supplied exog-
enously (Fig. 3), as the heart will preferentially oxidise 
exogenously supplied fatty acids over endogenous lipid 
stores (Saddik et al. 1993; Saddik and Lopaschuk 1991). 
Likewise, fatty acid oxidation is known to inhibit glucose 
oxidation via the Randle cycle (Hue et al. 2009; Randle 
et al. 1963), and therefore it is not surprising to see that 
provision of triacylglycerol results in lower glucose oxida-
tion than when glucose alone was present in the perfusion 
buffer (Fig. 4b vs. Fig. 3; 58.0% vs. 79.1%). That glucose 
oxidation exceeds fatty acid oxidation in this Langendorff 
preparation may reflect the proportions of glucose and 
Intralipid available to the heart. The 11 mM KH buffer 
glucose concentration is more than twice that in the blood 
of a normal rat under fasted conditions (Bell et al. 2011).
3.4  Strengths and limitations of the model
A strength of this model is that it considers entire isotopo-
logue distributions and the fate of individual labelled car-
bons. Analysis cannot be simplified to the assumption that 
one specific labelled isotopologue alone signifies greater 
oxidation of the labelled substrate. Indeed, it is possible to 
see from LC–MS measurement of isotopologue distribution 
that as the proportion of the glucose available to the heart 
which is U-13C labelled increases, the proportion of some 
labelled Krebs cycle intermediates (such as 2 + amu isoto-
pomers) actually decreases. The model illustrates that all 
levels of 2 + amu intermediates can correspond to more than 
one value of α (Fig. 2). The unlabelled and fully labelled 
isotopologues are exceptions, as each concentration corre-
sponds to only one α value. Use of these two isotopologues 
alone to assess α would be possible, however resolution 
would be lost because their levels change less rapidly at 
mid-levels of α. At low α there is also no fully-labelled iso-
topologue, so if considering these two isotopologues alone 
it would be possible to falsely conclude that there was no 
labelling. It is therefore imperative to consider the entire 
isotopologue distribution rather than specific individual 
isotopologues.
Consideration of the entire isotopologue distribution also 
allows us to avoid any impact of natural labelling abundance. 
As can be seen from Fig. 3, natural abundance of 13C label-
ling in the Krebs cycle results in a very low proportion of 
A model for determining cardiac mitochondrial substrate utilisation using stable 13C-labelled…
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Fig. 3  Isotope distribution plots showing the labelling distribution 
of glutamate, succinate and malate when the percentage of glucose 
in the perfusion buffer which was U-13C labelled was 0%, 25%, 50%, 
75% or 100% (each n = 3). Values displayed as mean ± SEM. Note 
that owing to the small value of the SEM relative to the mean, the 
SEM is highlighted in grey on some bars
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1 + amu labelling and essentially no labelling of 2 + amu 
or higher. As 13C labelling from U-13C labelled metabolites 
increases by an unknown factor, this low level of abundance 
would decrease by the same unknown factor due to reduced 
influx of “natural” carbon, making it difficult to correct for. 
However, since our model gives equal weighting to all iso-
topologues in the distribution, this minimises the impact of 
the negligible 1 + amu labelling originating from natural 
13C abundance.
The model also accounts for migration of labelled carbon 
within intermediates. This is significant because not doing 
so may lead to assumptions that carbons in positions not 
corresponding to the acetyl-CoA which was incorporated 
in that turn of the cycle were labelled via other pathways. 
However, our model demonstrates that this labelling can be 
accounted for by the natural intra-molecular migration of 
13C originating from acetyl-CoA as the cycle progresses.
The proposed metabolic network model, described in 
Supplementary Table 1–3, does not include reactions related 
to pyruvate carboxylation, and hence is not designed to 
assess flux via this pathway. Negligible anaplerosis is there-
fore an underlying assumption of this network model. In 
A B
C D
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
m
/z
+6
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
m
/z
+6
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
m
/z
+6
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
Malate MalateCitrate Citrate
Succinate Succinateα-ketoglutarate Glutamate
Pr
op
or
o
n 
of
 T
ot
al
 P
oo
l
Pr
op
or
o
n 
of
 T
ot
al
 P
oo
l
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
m
/z
+6
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
m
/z
+5
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
+1
m
/z
+2
m
/z
+3
m
/z
+4
0
0.2
0.4
0.6
0.8
1
m
/z
m
/z
 +
 1
m
/z
 +
 2
m
/z
 +
 3
m
/z
 +
 4
m
/z
 +
5
m
/z
 +
 6
MalateMalate CitrateCitrate
SuccinateSuccinate Glutamateα-ketoglutarate
Pr
op
or
o
n 
of
 T
ot
al
 P
oo
l
Pr
op
or
o
n 
of
 T
ot
al
 P
oo
l
Fig. 4  a Isotopologue distributions predicted by the model at 
α = 0.145 for malate, citrate, α-ketoglutarate and succinate. b Iso-
topologue distributions for malate, citrate, glutamate and succinate 
measured in heart tissue perfused for 32 min with 25%  U13C labelled 
glucose by LC–MS (n = 7, displayed as mean ± SEM). c Isotopo-
logue distributions predicted by the model at α = 0.089 for malate, 
citrate, α-ketoglutarate and succinate. d Isotopologue distributions 
for malate, citrate, glutamate and succinate measured in heart tissue 
perfused for 32 min with 25%  U13C labelled triglycerides by LC–MS 
(n = 7, displayed as mean ± SEM). All hearts were perfused with a 
total of 11 mM glucose and 0.4 mM equivalent triglyceride
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other organs or metabolic conditions where greater levels of 
pyruvate carboxylase flux would be expected, there would 
be a greater level of 3 + amu and heavier isotopologues. A 
larger discrepancy between our model’s prediction and the 
shape of distribution in the experimentally-measured dataset 
would be therefore observed. In the heart, however, even 
at levels of pyruvate carboxylase flux such as 5–10%, we 
would expect no significant deviance between the observed 
isotopologue distributions and those predicted by our model. 
For other conditions, where anaplerosis is expected to be 
significant, a more complex model should be considered.
As well as glucose, lactate may act as a source of pyru-
vate for oxidation in the Krebs cycle (Lloyd et al. 2003). 
Oxidation of circulating lactate may also be measured using 
this model. In the experiments described in this paper, no 
lactate was included in the initial buffer composition, so any 
present has been generated from pyruvate, and will exhibit 
an identical isotopologue distribution to that of pyruvate at 
steady state. Other experiments with an exogenous supply 
of labelled lactate may behave differently, in which case this 
model could be employed to determine exogenous lactate 
oxidation.
An assumption this model makes is that at steady state 
metabolite fluxes are constant and therefore isotopologue 
distributions are unlikely to differ between subcellular com-
partments. Were it to transpire that this is not the case, there 
would be no impact on the validity of the model, but in order 
to test mitochondrial metabolites they should be extracted 
from isolated mitochondria preparations rather than whole 
tissue.
Back-flux, whereby the reverse reaction of Krebs cycle 
enzymes occurs, is accounted for in the model because the 
stoichiometry is the same regardless of reaction direction or 
rate. For example, if one isotopologue of fumarate precedes 
50:50 proportions of a malate isotopologue, the reverse reac-
tion will convert both malate isotopologues back to the same 
isotopologue of fumarate, so it does not influence isotopo-
logue distribution.
One limitation of the model in its current format is that it 
assumes all acetyl-CoA is either 0 + or 2 + amu. No 1 + amu 
acetyl-CoA was used in this work, so this was not needed 
here, but the model could easily be adjusted to account for 
this if required.
4  Concluding remarks
This mathematical model has been developed for the analy-
sis of 13C labelling patterns of Krebs cycle intermediates and 
has been demonstrated to accurately interpret isotopologue 
distributions which result from the whole range of different 
labelling inputs from  U13C labelled substrates.
Potential applications of the model might include assess-
ment of metabolic substrate preference under different 
physiological or pathological conditions. One such paradigm 
would be the failing heart, which is incapable of supply-
ing itself with sufficient blood and oxygen for sustenance 
of contractile function (Dargie 2005). This is thought to 
lower overall substrate oxidation, but increase the ratio of 
glucose:fatty acids oxidised (Neubauer 2007). This model 
could be used to assess progression of failure via the per-
centage contribution of glucose oxidation to total substrate 
oxidation by the Krebs cycle.
Author contributions RTL conceived and designed the study, and 
authored the manuscript. RTL & DD constructed the mathematical 
model. RTL and DM-J conducted the ex vivo experiments. RTL & 
JAW conducted mass spectrometry analysis of frozen tissue. RTL & 
DD analysed the data. AJM and JLG provided conceptual and edito-
rial guidance, designed experiments and revised the manuscript. All 
authors read and approved the final manuscript.
Funding This work was supported by the British Heart Foundation 
[grant number FS/14/59/31282].
Data availability The datasets generated during and/or 
analysed during the current study are available in the Uni-
versity of Cambridge repository, https ://doi.org/10.17863 /
CAM.39870 .
Code availability The MATLAB model generated during 
this study is available in the University of Cambridge reposi-
tory, https ://doi.org/10.17863 /CAM.39868 .
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, 
T. C., et al. (2016). The failing heart relies on ketone bodies as a 
fuel. Circulation, 115, 698–705.
 R. T. Lindsay et al.
1 3
 154  Page 10 of 10
Bell, R. M., Mocanu, M. M., & Yellon, D. M. (2011). Retrograde heart 
perfusion: The Langendorff technique of isolated heart perfusion. 
Journal of Molecular and Cellular Cardiology, 50(6), 940–950.
Chatham, J. C., Forder, J. R., Glickson, J. D., & Chance, E. M. (1995). 
Calculation of absolute metabolic flux and the elucidation of the 
pathways of glutamate labeling in perfused rat heart by 13C NMR 
spectroscopy and nonlinear least squares analysis. Journal of Bio-
logical Chemistry, 270, 7999–8008.
Crown, S. B., & Antoniewicz, M. R. (2013). Publishing 13C metabolic 
flux analysis studies: A review and future perspectives. Metabolic 
Engineering, 20, 42–48.
Crown, S. B., Kelleher, J. K., Rouf, R., Muoio, D. M., & Antoniewicz, 
M. R. (2016). Comprehensive metabolic modeling of multiple 
13C-isotopomer data sets to study metabolism in perfused working 
hearts. American Journal of Physiology-Heart and Circulatory 
Physiology, 311(4), H881–H891.
Dargie, H. (2005). Heart failure post-myocardial infarction: A review 
of the issues. Heart, 91, 3–6.
Hue, L., Taegtmeyer, H., Randle, P., Garland, P., & Hales, N. (2009). 
The Randle cycle revisited: A new head for an old hat. Ameri-
can Journal of Physiology. Endocrinology and Metabolism, 297, 
578–591.
Katzs, J., Walss, P., & Lee, W. N. (1993). Isotopomer studies of glu-
coneogenesis and the Krebs cycle with 13C-labeled lactate. The 
Journal of Biological Chemistry, 268(34), 25509–25521.
Khairallah, M., Labarthe, F., Bouchard, B., Danialou, G., Petrof, B. J., 
& Des Rosiers, C. (2004). Profiling substrate fluxes in the isolated 
working mouse heart using 13 C-labeled substrates: Focusing on 
the origin and fate of pyruvate and citrate carbons. American 
Journal of Physiology-Heart and Circulatory Physiology, 286(4), 
H1461–H1470.
Krebs, H. A., Salvin, E., & Johnson, W. (1938). The formation of citric 
acid and α-ketoglutaric acids in the mammalian body. The Bio-
chemical Journal, 32(1), 113–117.
Le Belle, J. E., Harris, N. G., Williams, S. R., & Bhakoo, K. K. (2002). 
A comparison of cell and tissue extraction techniques using high-
resolution 1H-NMR spectroscopy. NMR in Biomedicine, 15(1), 
37–44.
Lewandowski, E. D., & Hulbert, C. (1991). Dynamic changes in 
13C NMR spectra of intact hearts under conditions of varied 
metabolite enrichment. Magnetic Resonance in Medicine, 19(1), 
186–190.
Lewandowski, E. D., White, L. T., Damico, L. A., Yu, X., Doumen, 
C., & LaNoue, K. F. (1996). Multiplet structure of 13C NMR 
signal from glutamate and direct detection of tricarboxylic acid 
(TCA) cycle intermediates. Magnetic Resonance in Medicine, 
35(2), 149–154.
Liu, J., Wang, P., Douglas, S. L., Tate, J. M., Sham, S., Lloyd, S. 
G., et al. (2016). Impact of high-fat, low-carbohydrate diet on 
myocardial substrate oxidation, insulin sensitivity, and cardiac 
function after ischemia-reperfusion. American Journal of Phys-
iology-Heart and Circulatory Physiology, 44, 1–10.
Lloyd, S., Brocks, C., & Chatham, J. C. (2003). Differential modula-
tion of glucose, lactate, and pyruvate oxidation by insulin and 
dichloroacetate in the rat heart. American Journal of Physiology-
Heart and Circulatory Physiology, 285, 163–172.
Lloyd, S. G., Wang, P., Zeng, H., Chatham, J. C., Steven, G., Wang, 
P., et al. (2004). Impact of low-flow ischemia on substrate oxida-
tion and glycolysis in the isolated perfused rat heart. American 
Journal of Physiology-Heart and Circulatory Physiology, 287, 
H351–H362.
Melo, T. M., Haberg, A. K., Risa, Ø., Kondziella, D., Pierre-gilles, H., 
& Sonnewald, U. (2011). Tricarboxylic acid cycle activity meas-
ured by 13C magnetic resonance spectroscopy in rats subjected to 
the Kaolin model of obstructed hydrocephalus. Neurochemical 
Research, 36, 1801–1808.
Neubauer, S. (2007). The failing heart—An engine out of fuel. The New 
England Journal of Medicine, 356, 1140–1151.
Randle, P., Garland, M., Hales, C., & Newsholme, E. (1963). The glu-
cose fatty-acid cycle: Its role in insulin sensitivity and the meta-
bolic disturbances of diabetes mellitus. The Lancet, 281(7285), 
785–789.
Saddik, M., Gamble, J., Witters, L. A., & Lopaschuk, G. D. (1993). 
Acetyl-CoA carboxylase regulation of fatty acid oxidation in the 
heart. Journal of Biological Chemistry, 268(34), 25836–25845.
Saddik, M., & Lopaschuk, G. D. (1991). Myocardial triglyceride turno-
ver and contribution to energy. The Journal of Biological Chem-
istry, 266(13), 8162–8170.
Taegtmeyer, H., Young, M. E., Lopaschuk, G. D., Abel, E. D., Brunen-
graber, H., Darley-Usmar, V., et al. (2016). Assessing cardiac 
metabolism—A scientific statement from the American Heart 
Association. Circulation Research, 118(10), 1659–1701.
Yang, L., Kasumov, T., Kombu, R. S., Zhu, S., Cendrowski, A. V., 
David, F., et al. (2008). Metabolomic and mass isotopomer analy-
sis of liver gluconeogenesis and citric acid cycle. The Journal of 
Biological Chemistry, 283(32), 21988–21996.
Yu, X., White, L. T., Lewandowski, E. D., Damico, L. A., Kathryn, F., 
& Alpert, N. M. (1995). Kinetic analysis of dynamic 13C NMR 
spectra: Metabolic flux, regulation, and compartmentation in 
hearts. Biophysical Journal, 69(5), 2090–2102.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
